{"id":1415,"date":"2026-05-12T15:00:00","date_gmt":"2026-05-12T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1415"},"modified":"2026-04-08T20:37:20","modified_gmt":"2026-04-08T20:37:20","slug":"khavinson-bioregulators-the-complete-research-guide-to-epitalon-pinealon-prostamax-short-chain-peptides","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/khavinson-bioregulators-the-complete-research-guide-to-epitalon-pinealon-prostamax-short-chain-peptides\/","title":{"rendered":"Khavinson Bioregulators: The Complete Research Guide to Epitalon, Pinealon, Prostamax & Short-Chain Peptides"},"content":{"rendered":"

There\u2019s a category of peptide research that\u2019s been running for over forty years, produced hundreds of peer-reviewed papers, and has largely flown under the radar of Western geroscience \u2014 until recently. Khavinson bioregulators sit at the intersection of aging biology, epigenetics, and tissue-specific gene regulation. Short-chain peptides, usually two to four amino acids, with proposed mechanisms involving chromatin remodeling and transcriptional control. The science is old enough to have a real literature behind it. It\u2019s also unusual enough that investigators approaching it for the first time benefit from some orientation.<\/p>\n

This guide covers the framework, the key compounds \u2014 Epitalon, Pinealon, Prostamax<\/a> \u2014 and several others that appear consistently in the geroscience literature. It also covers where the evidence is genuinely strong, where it\u2019s weaker, and what the honest research questions look like in 2025\u20132026. For laboratory and preclinical research use only.<\/p>\n\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n